medigraphic.com
ISSN 0016-3813 (Impreso)

2002, Número S1

<< Anterior Siguiente >>

Gac Med Mex 2002; 138 (S1)


Actualidades en hemostasia

I. Nuevos conceptos en la fisiología de la coagulación
II. Proteína Z, TAFI y Anexinas como proteínas reguladoras de la coagulación sanguínea
III. Actualidades en el diagnóstico y la clasificación de la enfermedad de Von Willebrand
IV. Coagulación intravascular diseminada

Quintana-González S, Martínez-Murillo C, Jiménez R, Flores-Chapa JD

Idioma: Español
Referencias bibliográficas: 50
Paginas: 47-60
Archivo PDF: 234.75 Kb.


FRAGMENTO

Introducción

La hemostasia representa el cese fisiológico de la hemorragia por un mecanismo complejo que involucra un cambio de estado físico; de líquido a sólido con la formación de fibrina, y el enlace del coágulo en una malla insoluble. Las características de la coagulación sanguínea requieren que las reacciones sean localizadas, amplificadas, reguladas, autolimitadas y transitorias en el tiempo.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Quintana GS, Martínez MC, Ambriz F Raúl. Fisiología de la coagulación. En: Martínez-Murillo C, Quintana GS, Ambríz FR, Kasper C, editors. Hemofilia. México: Ed. Prado. 2001. p. 19-42.

  2. Quintana GS, Martínez MC. Fisiología de la hemostasia secundaria. En: Manual de hemostasia y trombosis. México: Editorial Prado; 1996. p. 23-48.

  3. Miale JB. Hemostasis and blood coagulation. In: Laboratory medicine hematology. 3rd ed. St. Louis, The CV Mosby Company; 1967. p. 999.

  4. Waaler BA. Simultaneous contribution to the formation of thrombin by the intrinsic and extrinsic blood clotting systems. Scand J Clin Lab Invest 1957; 9:322-330.

  5. MacFarlane RG. An enzyme cascade in blood clotting mechanism and its function as a biochemical amplifier. Nature 1964;202:498-499.

  6. Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science 1964;145:1310-1312.

  7. Hoffman M, Monroe DM. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Sem Hematol 38 (suppl 12): 6-9.

  8. Mannucci PM, Tuddenham EGD. Medical Progress: The Hemophilias-From Royal genes to gene therapy. N Engl J Med 2001;344(23);1773-1779.

  9. Osterud B, Rapaport S. Activation of factor IX by the reaction product of tissue factor and factor VII. Additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977;74:5260-5264.

  10. Davie EW. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 1995;74:1-6.

  11. Rapaport SI, Rao LVM. The tissue factor pathway: How it has become a “prima ballerina”. Thromb haemost; 74: 7-12.

  12. Morrisey JH, Fakhrai H, Edgington TS. Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade. Cell 1987;50:129-135.

  13. Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 1990; 87:6934-6938.

  14. Harlos K, Martin DMA, O’Brien DP, Jones EY, Stuart DI, Polikarpov I, Miller A, Tuddenham EGD, Boys CWG. Crystal structure of the extracellular region of human tissue factor. Nature 1994;370: 662-666.

  15. Muller YA, Ultsch MH, de Vos AM. Structure of the extracellular domain of human tissue factor: location of the factor VIIa binding site. Biochemistry 1994;33:10864-10870.

  16. Jurlander B, Thim L, Klausen NK, Persson E, Kjalke M, Rexen P, Jorgensen TB, Ostergaard PB, Erhardtsen E, Bjorn SE. Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development. Sem Thromb Haemost 2001;27:373-383.

  17. Osterud B. The role of platelets in decrypting monocyte tissue factor. Sem Hematol; 2001;38:2-5.

  18. Versteeg HH, Peppenlenbosch MP, Spek CA. The pleiotropic effects of tissue factor: a possible role for factor VIIa-induced intracellular signaling? Thromb Haemost 2001;86:1353-9.

  19. Dvorak HF, Senger DR. Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastasis Rev 1983;2:41-73.

  20. Fifler IJ. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res 1978;38:2651-2660.

  21. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau’s syndrome revisited. Blood 1983;62:14-31.

  22. Hu T, Bach RR, Horton R, Konigsberg WH, Todd MB. Procoagulant activity in cancer cells is dependent on tissue factor expression. Oncol Res 1994;6:321-327.

  23. Murray JC. Coagulation and cancer. Br J Cancer 1991;64:422-424.

  24. Constantini S, Kornowski R, Pomeranz S, Rappaport ZH. Thromboembolic phenomena in neurosurgical patients operated upon for primary and metastatic brain tumors. Acta Neurochir 1991;109:93-7.

  25. Koningsberg W, Kirchhofer D, Riederer MA, Nemerson Y. The TF:VIIa complex: clinical significance, structure-function relationships and its role in signaling and metastasis. Thromb Haemost 2001;86:757-771.

  26. Martínez-Murillo C, Quintana González S. Fisiología de la hemostasia primaria. Manual de hemostasia y trombosis. México, D.F.: Editorial Prado; 1996. p. 5-22.

  27. Quintana-González S, Martínez-Murillo C. Fisiología de la hemostasia secundaria. Manual de hemostasia y trombosis. México, D.F.: Editorial Prado; 1996. p. 23-48.

  28. Dahlbäck B. Blood coagulation. The Lancet 2000; 355:1627-1632.

  29. Kemkes-Matthes B, Matthes KJ. Protein Z. Sem Thromb Haemost 2001;5:551-556.

  30. Han X, Fiehler R, Broze GJ. Characterization of the protein Z-dependent protease inhibitor. Blood 2000;96:3049-3055.

  31. Ravi S, Mauron T, Lammle B, Wuillemin W. Protein Z in healthy human individuals and in patients with a bleeding tendency. Br Haematol 1998;5:1219-1223.

  32. Yin ZF, Huang ZF, Cui J. Prothrombotic phenotype of protein Z deficiency. Proc. Natl Acad Sci USA 2000;97:6734-6738.

  33. Nagashima M, Yin ZF, Zhao L, White K, Zhu Y, Lasky N, Halks-Miller M, Broze GJ, Fay WP, Morser J. Thrombin-activable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest 2002;1:101-110.

  34. Hori Y, Gabazza EC, Yano Y, Katsuki A, Suzuki K, Adachi Y, Sumida Y. Insulin resístanse is associated with increased circulating level of thrombin-activable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab 2002;2:660-665.

  35. Chris P, Reutelingsperger M. Annexins: key regulators of haemostasis, thrombosis and apoptosis. Thromb Haemost 2001;86:413-419.

  36. Menell JS, Cesarman GM, Jacovina AT, McLaughlin MA, Lev EA, Hajjar KA. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999;340:994-1004.

  37. Rand JH. "Annexinopathies" a new class of diseases. N Engl J Med 1999;340:1035-1036.

  38. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand´s disease. Blood 1987;69:454-59.

  39. Valverde BE, Jiménez R, Mora LA, Zúñiga ME. Prevalencia de la enfermedad de von Willebrand en niños escolares costarricenses. Tesis, Universidad de Costa Rica 1991.

  40. Diez-Ewald M, Vizcaíno G, Arteaga-Vizcaíno M, Fernández N, Weir-Medina J, Gómez O. Epidemiology of von Willebrand disease in the state of Zulia, Venezuela. Invest Clin 1991;32: 187-99.

  41. Ruggeri ZM. Developing basis and clinical research on von Willebrand factor and von Willebrand disease. Thromb Haemost 2000;84:147-9.

  42. Sadler JE, Mannucci PM, Berntorp E, Bochkov N, Boulyjenkov V, Ginsburg D, Meyer D, Peake I, Rodeghiero F, Srivastava A. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000;84:160-74.

  43. Fressinaud E, Veyradier A, Truchaud F, Martin I, Boyer-Neuman C, Trossaert M, Meyer D. Screening for von Willebrand disease with a new analyser using high shear stress: a study of 60 cases. Blood 1998;91:1325-31.

  44. Peake I, Rodeghiero F, Srivastava A. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84:160-74.

  45. Paby C. Coagulaciones intravasculares diseminadas y localizadas. 1st ed. Toray-Masson; 1976.

  46. Colman RW, Hirsh J, Marder VJ, Salzman EW, editors, Hemostasis and thrombosis: basic principies and clinical practice. 3rd ed. Philadelphia, PA, USA: JB Lippincott Company, 1994.

  47. Toch CH. Laboratory testing in disseminated intravascular coagulation. Semin Throm Hemost 2001 Dec;27(6):653-6.

  48. Maxson JH. Management of dissemidated intravascular coagultion. Crit Care Nurs Clin North Am 2000 Sep;12(3):341-52.

  49. de Jonge E, van del Poll T, Kesecioglu J, Levi M. Anticoagulant factor concentrates in disseminated intravascular coagulation: rationale for use and clinical experience. Semin Thromb Hemost 2001 Dec;27(6):667-74.

  50. Opal SM. Clinical impact of novel antocoagulation strategies in sepsis. Curr Opin Crit Care 2001Oct;7(5):347-53.




2020     |     www.medigraphic.com